Crestor (Rosuvastatin) Cost in Iowa: 2026 Prices, Insurance, and Savings

What Crestor and Generic Rosuvastatin Actually Cost in Iowa

The price gap between brand Crestor and its generic equivalent in Iowa is enormous. Brand Crestor carries an AstraZeneca list price near $290 per month, a figure that has barely moved since patent expiration in 2016. Generic rosuvastatin, by contrast, averages just $15 per month across Iowa retail pharmacies in 2026.

That $275 monthly spread means choosing generic saves an Iowa patient over $3,300 annually for the same active compound at the same dose. Rosuvastatin calcium tablets are rated AB-equivalent to Crestor by the FDA, meaning they meet identical bioequivalence standards for absorption and clinical effect. The FDA Orange Book confirms multiple manufacturers hold approved abbreviated new drug applications for rosuvastatin calcium in 5 mg, 10 mg, 20 mg, and 40 mg strengths.

Prices vary by pharmacy. Hy-Vee, Walgreens, CVS, and Costco locations across Des Moines, Cedar Rapids, and Iowa City each set their own cash-pay rates. Costco pharmacies in Iowa typically price generic rosuvastatin between $4 and $8 for a 30-day supply without insurance. Walgreens and CVS tend to run slightly higher, in the $12 to $18 range, though discount coupons often bring these down to $6 or less.

Patients filling at independent Iowa pharmacies should always ask for the cash price alongside their insurance copay. In some cases the uninsured cash price for generic rosuvastatin is lower than the insured copay, particularly for patients on high-deductible health plans.

Iowa Medicaid and Rosuvastatin Coverage

Iowa Medicaid does not cover brand-name Crestor as of 2026. This exclusion applies to both fee-for-service Medicaid and Iowa's managed care organizations (MCOs), which currently include Amerigroup Iowa and Molina Healthcare of Iowa.

Generic rosuvastatin, though, sits on a different formulary tier. Iowa Medicaid's preferred drug list (PDL) includes several generic statins. Atorvastatin and simvastatin occupy the preferred tier, and rosuvastatin may require prior authorization depending on the MCO. The Iowa Department of Health and Human Services publishes its PDL quarterly, and prescribers should verify current tier placement before writing a prescription.

For Medicaid enrollees who need rosuvastatin specifically (due to intolerance of atorvastatin or failure to reach LDL targets on other statins), prior authorization documentation should include trial-and-failure evidence. The 2018 AHA/ACC cholesterol guidelines recommend high-intensity statin therapy for patients with clinical ASCVD, and rosuvastatin 20 to 40 mg daily qualifies as high-intensity per those guidelines. Citing guideline-based medical necessity strengthens PA requests.

Iowa Medicaid copays for preferred generic drugs are typically $1 to $3 per prescription. If rosuvastatin gains preferred status through PA approval, the out-of-pocket cost drops to near zero for qualifying enrollees.

Private Insurance Coverage Across Iowa

Most commercial health plans sold in Iowa cover generic rosuvastatin on Tier 1 or Tier 2 of their formularies. Wellmark Blue Cross Blue Shield, the dominant private insurer in the state, lists rosuvastatin calcium as a preferred generic with copays ranging from $5 to $15 per 30-day supply. The 2018 ACC/AHA guideline update specifically identifies rosuvastatin as a first-line option for LDL reduction, which supports formulary inclusion across payers.

UnitedHealthcare plans available through Iowa's ACA marketplace similarly cover generic rosuvastatin. Medica, which serves several Iowa counties, places it on their generic tier with copays under $10 for most plan designs.

Brand Crestor coverage through private insurance is rare in 2026. Even when technically listed, brand-name statins often sit on Tier 3 (non-preferred brand) or require step therapy showing generic failure. The practical result: almost no Iowa patient pays for brand Crestor through insurance unless they have a documented allergy or intolerance to generic formulation excipients.

Employer-sponsored plans in Iowa follow a similar pattern. A 2024 Kaiser Family Foundation employer survey found that 94% of covered workers had prescription drug benefits with tiered cost-sharing, and generic statins consistently occupied the lowest tier. Iowa employers with self-funded plans can negotiate formulary placement directly, but the economic incentive always favors generic rosuvastatin.

Compounded Rosuvastatin in Iowa: Legal Status and Pricing

Compounded rosuvastatin is legal in Iowa through licensed 503A compounding pharmacies. These pharmacies operate under both Iowa Board of Pharmacy oversight and Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits patient-specific compounding based on a valid prescription.

The distinction matters. 503A pharmacies compound medications for individual patients with prescriptions. 503B outsourcing facilities compound without patient-specific prescriptions and ship in bulk. Both operate in Iowa, but 503A is the more common route for individual patients seeking compounded rosuvastatin.

Why would a patient choose compounded rosuvastatin? A few reasons apply. Some patients need a dose not commercially available (say, 7.5 mg). Others cannot tolerate certain inactive ingredients in manufactured tablets, such as lactose monohydrate or crospovidone. Compounding pharmacies can formulate rosuvastatin in capsules, suspensions, or alternate tablet bases that avoid specific excipients.

Pricing varies. Some compounding pharmacies offering rosuvastatin through telehealth platforms price it with no additional cost to the patient when bundled into a membership or consultation fee. Stand-alone compounded rosuvastatin from Iowa 503A pharmacies typically costs between $20 and $50 per month depending on dose and formulation.

Iowa does not restrict telehealth-initiated prescriptions for compounded medications as long as the prescriber holds an active Iowa medical license and establishes a valid provider-patient relationship. The Iowa Board of Medicine's telemedicine rules allow synchronous video or audio encounters to satisfy this requirement.

How Rosuvastatin Reduces Cardiovascular Risk: The Evidence

Rosuvastatin earned its place in clinical practice through large, well-designed trials. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin), published in the New England Journal of Medicine in 2008, remains the landmark study. JUPITER enrolled 17,802 apparently healthy men and women with LDL cholesterol below 130 mg/dL but elevated high-sensitivity C-reactive protein (hsCRP above 2.0 mg/L).

Participants received rosuvastatin 20 mg daily or placebo. The trial was stopped early at a median follow-up of 1.9 years. Results were striking.

Rosuvastatin reduced LDL cholesterol by 50% and hsCRP by 37%. The primary endpoint (a composite of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death) dropped by 44% in the rosuvastatin group (hazard ratio 0.56 to 95% CI 0.46 to 0.69, P<0.00001). The number needed to treat (NNT) to prevent one primary endpoint event over 2 years was 95.

These numbers shaped guidelines worldwide. The 2018 AHA/ACC cholesterol management guideline incorporated JUPITER's findings into its risk-enhancement factor framework, noting that elevated hsCRP (2.0 mg/L or higher) in intermediate-risk patients favors initiating statin therapy.

For Iowa patients weighing whether rosuvastatin is worth the cost, even at $15 per month, JUPITER's data provide a clear answer for those who meet prescribing criteria. A 44% reduction in major cardiovascular events at a cost of roughly $180 per year represents one of the highest-value interventions in preventive medicine.

The METEOR trial further demonstrated rosuvastatin's effect on atherosclerosis progression. In 984 patients with subclinical atherosclerosis, rosuvastatin 40 mg daily significantly reduced the rate of change in maximum carotid intima-media thickness compared to placebo over 2 years (P<0.0001).

Telehealth Prescribing of Rosuvastatin in Iowa

Iowa permits telehealth prescribing of rosuvastatin without geographic restriction within the state. A prescriber licensed in Iowa can evaluate a patient via synchronous video, review labs, and transmit an electronic prescription to any Iowa pharmacy (retail or compounding) in the same encounter.

Iowa's telehealth parity law requires commercial insurers to cover telehealth visits at the same rate as in-person visits. This means the encounter itself should not cost more simply because it happens over video. Medicaid telehealth coverage in Iowa follows CMS guidelines and extends to evaluation and management visits appropriate for statin prescribing.

Several national telehealth platforms serve Iowa patients seeking statin prescriptions. These platforms typically charge $30 to $75 for an initial consultation and can order lipid panels through partnerships with Quest Diagnostics or Labcorp locations in Des Moines, Cedar Rapids, Davenport, and Sioux City.

For patients already taking rosuvastatin who move to Iowa or switch providers, telehealth offers continuity without a gap in medication access. Iowa does not impose a mandatory in-person visit before telehealth prescribing of maintenance medications like statins, which distinguishes it from states that require an initial face-to-face encounter for controlled substances (rosuvastatin is not a controlled substance).

One consideration: lab monitoring. The 2018 AHA/ACC guidelines recommend a fasting lipid panel 4 to 12 weeks after initiating statin therapy and then every 3 to 12 months as clinically indicated. Telehealth platforms that include lab ordering in their workflow tend to produce better adherence to monitoring schedules than those that leave lab coordination to the patient.

Discount Programs and Savings Cards Available in Iowa

Multiple pathways exist to reduce rosuvastatin costs below the average $15 per month cash price in Iowa. Generic discount programs at major retailers represent the first option. Walmart's $4 generics list includes several statins, and while rosuvastatin pricing varies by location, many Iowa Walmart pharmacies offer 30-day supplies of rosuvastatin 10 mg or 20 mg for $4 to $9.

GoodRx, RxSaver, and similar coupon aggregators show Iowa-specific pricing. As of mid-2026, GoodRx lists generic rosuvastatin 10 mg (30 tablets) at $4 to $12 depending on the Iowa pharmacy. These coupons work for uninsured patients and can sometimes beat insurance copays.

For patients who require brand Crestor (documented generic intolerance, physician-directed), AstraZeneca's savings programs may apply. The manufacturer periodically offers copay cards that reduce brand Crestor costs to $3 to $30 per month for commercially insured patients. These cards do not apply to government insurance (Medicare Part D, Medicaid, TRICARE). Eligibility and terms change frequently, so patients should verify current offers directly with AstraZeneca.

Mark Cuban Cost Plus Drugs offers rosuvastatin at transparent markup pricing. Their model adds a flat 15% margin plus a $5 pharmacy fee to the manufacturer's cost, which for rosuvastatin typically results in prices between $4 and $7 per month with home delivery to Iowa addresses.

Patient assistance programs (PAPs) serve uninsured Iowa residents who fall below income thresholds. The NeedyMeds database catalogs available programs, and Iowa's community health centers can assist with applications. For a $15 per month generic, PAPs are less commonly needed than for expensive brand medications, but they remain an option for patients facing financial hardship.

Dosing, Safety, and Monitoring Considerations

Rosuvastatin is prescribed at 5 mg to 40 mg once daily. Most Iowa prescribers start at 10 mg or 20 mg depending on LDL reduction goals and patient risk category. The FDA-approved prescribing information recommends a starting dose of 10 mg for most patients, with 5 mg reserved for those at higher risk of myopathy (including patients of Asian descent, those with severe renal impairment, or those taking certain interacting medications like cyclosporine).

High-intensity therapy (rosuvastatin 20 to 40 mg) targets a 50% or greater LDL reduction. In JUPITER, the 20 mg dose achieved a mean 50% LDL reduction from baseline, and the 2018 AHA/ACC guidelines classify rosuvastatin 20 to 40 mg as high-intensity statin therapy.

Common side effects include myalgia (reported in 2% to 11% of patients across trials), headache, nausea, and abdominal pain. Serious adverse effects such as rhabdomyolysis are rare. The JUPITER trial reported no significant difference in serious adverse events between rosuvastatin and placebo groups over the study period, though a small increase in physician-reported diabetes was observed (3.0% vs 2.4%, P=0.01).

Liver function testing before initiation and as clinically indicated thereafter is standard practice. Routine periodic liver enzyme monitoring is no longer recommended by the FDA for statin therapy, a change reflected in the 2012 FDA safety communication.

Iowa prescribers should note the drug interaction between rosuvastatin and gemfibrozil. Coadministration increases rosuvastatin exposure roughly 2-fold, raising myopathy risk. Fenofibrate, by contrast, does not significantly alter rosuvastatin pharmacokinetics and is the preferred fibrate combination when triglyceride-lowering is needed alongside statin therapy.

How Iowa Compares to Neighboring States

Generic rosuvastatin pricing in Iowa ($15 average) aligns closely with neighboring Midwestern states. Minnesota averages $14 per month, Illinois $16, and Nebraska $15. Wisconsin runs slightly higher at $17. These differences are modest and driven primarily by pharmacy benefit manager contracts and local competition density.

The more meaningful difference is Medicaid coverage. Minnesota Medicaid covers generic rosuvastatin on its PDL without prior authorization. Illinois Medicaid similarly includes rosuvastatin as a preferred generic statin. Iowa's Medicaid formulary, which may require PA for rosuvastatin while preferring atorvastatin, stands as a notable exception in the region.

For Iowa patients near state borders (the Quad Cities, Sioux City, or Omaha metro area), filling prescriptions across state lines is legal but insurance networks may not cover out-of-state pharmacies. Cash-pay pricing at out-of-state pharmacies is always an option, though the $1 to $3 price difference rarely justifies the trip.

The broader point: rosuvastatin is inexpensive everywhere in Iowa. The clinical question (whether you need a statin and which statin is right for you) matters far more than the cost question in 2026. At $15 per month or less, the financial barrier to statin therapy in Iowa is effectively gone for generic rosuvastatin.